12:00 AM
 | 
Aug 15, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Banzel rufinamide regulatory update

In June, Health Canada approved Banzel rufinamide from Eisai for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in children >=4 years of age and adults. Eisai markets the triazole...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >